Verve Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Verve Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| collaboration revenue | 32,976,000 | 13,080,000 | 6,865,000 | 6,692,000 | 5,695,000 | 5,144,000 | 3,117,000 | 2,093,000 | 1,404,000 | 1,012,000 | 929,000 | |||||
| operating expenses: | ||||||||||||||||
| research and development | 54,458,000 | 55,048,000 | 49,938,000 | 50,984,000 | 48,376,000 | 46,811,000 | 43,765,000 | 47,260,000 | 47,110,000 | 37,284,000 | 35,197,000 | 33,125,000 | 24,490,000 | 25,939,000 | 17,495,000 | 13,423,000 |
| general and administrative | 15,154,000 | 14,099,000 | 13,837,000 | 14,547,000 | 14,163,000 | 12,281,000 | 11,686,000 | 13,416,000 | 12,553,000 | 11,438,000 | 9,592,000 | 9,067,000 | 7,435,000 | 6,601,000 | 6,007,000 | 3,541,000 |
| total operating expenses | 69,612,000 | 69,147,000 | 63,775,000 | 65,531,000 | 62,539,000 | 59,092,000 | 55,451,000 | 60,676,000 | 59,663,000 | 48,722,000 | 44,789,000 | 42,192,000 | 31,925,000 | 32,540,000 | 23,502,000 | 16,964,000 |
| income from operations | -36,636,000 | -56,067,000 | -56,910,000 | -58,839,000 | -56,844,000 | -53,948,000 | -52,334,000 | -58,583,000 | -58,259,000 | -47,710,000 | -43,860,000 | -42,192,000 | -31,925,000 | -32,540,000 | -23,502,000 | -16,964,000 |
| yoy | -35.55% | 3.93% | 8.74% | 0.44% | -2.43% | 13.07% | 19.32% | 38.85% | 82.49% | 46.62% | 86.62% | 148.71% | ||||
| qoq | -34.66% | -1.48% | -3.28% | 3.51% | 5.37% | 3.08% | -10.67% | 0.56% | 22.11% | 8.78% | 3.95% | 32.16% | -1.89% | 38.46% | 38.54% | |
| operating margin % | ||||||||||||||||
| other income: | ||||||||||||||||
| change in fair value of success payment liability | 223,000 | -205,000 | -6,000 | 1,671,000 | 78,000 | -713,000 | 802,000 | -662,000 | 738,000 | 2,177,000 | -3,306,000 | 938,000 | 1,677,000 | 1,139,000 | 700,000 | -10,036,000 |
| interest and other income | 5,459,000 | 6,310,000 | 6,887,000 | 7,429,000 | 8,136,000 | 6,341,000 | 5,841,000 | 5,438,000 | 5,546,000 | 4,501,000 | 1,976,000 | 308,000 | 82,000 | |||
| total other income | 5,682,000 | 6,105,000 | 6,881,000 | 9,100,000 | 8,214,000 | 5,628,000 | 6,643,000 | 4,776,000 | 6,284,000 | 6,678,000 | -1,330,000 | 1,246,000 | 1,759,000 | 1,203,000 | 753,000 | -36,001,000 |
| income before benefit from income taxes | -30,954,000 | -49,962,000 | -50,029,000 | -49,739,000 | -48,630,000 | -48,320,000 | -45,691,000 | -53,807,000 | ||||||||
| benefit from income taxes | -79,000 | -73,000 | -104,000 | -66,000 | -106,000 | -32,000 | -67,000 | -176,000 | ||||||||
| net income | -31,033,000 | -50,035,000 | -50,133,000 | -49,805,000 | -48,736,000 | -48,352,000 | -45,758,000 | -53,983,000 | -51,975,000 | -41,085,000 | -45,190,000 | -40,946,000 | -30,166,000 | -31,337,000 | -22,749,000 | -52,965,000 |
| yoy | -36.32% | 3.48% | 9.56% | -7.74% | -6.23% | 17.69% | 1.26% | 31.84% | 72.30% | 31.11% | 98.65% | -22.69% | ||||
| qoq | -37.98% | -0.20% | 0.66% | 2.19% | 0.79% | 5.67% | -15.24% | 3.86% | 26.51% | -9.08% | 10.36% | 35.74% | -3.74% | 37.75% | -57.05% | |
| net income margin % | ||||||||||||||||
| net income per common share, basic and diluted | -350 | -580 | -590 | -590 | -590 | -690 | -720 | -870 | -840 | |||||||
| weighted-average common shares used in net income per share, basic and diluted | 88,795,827 | 84,722,277 | 84,632,952 | 84,226,523 | 83,132,960 | 63,211,849 | 61,953,992 | 61,787,403 | ||||||||
| comprehensive loss: | ||||||||||||||||
| other comprehensive loss: | ||||||||||||||||
| unrealized (loss) on marketable securities | -35 | |||||||||||||||
| comprehensive loss | -31,068 | -50,750 | -48,375 | -49,920 | -49,508 | -198,950,381 | -45,601 | -54,500 | -51,518 | -40,859 | -45,172 | -41,152 | -30,670 | |||
| unrealized gain on marketable securities | -715 | 1,758 | -772 | 965,903 | 157 | 457 | -226 | -5 | -4 | |||||||
| unrealized loss on marketable securities | -115 | -517 | -206 | -504 | ||||||||||||
| other comprehensive gain: | ||||||||||||||||
| change in fair value of antidilution rights liability | -25,970,000 | |||||||||||||||
| net income per common share attributable to common stockholders, basic and diluted | -650 | -790 | -840 | -620 | 40 | -470 | -6,660 | |||||||||
| weighted-average common shares used in net income per share attributable to common stockholders, basic and diluted | 54,023,653 | 57,207,125 | 48,674,873 | 48,571,214 | 26,872,036 | 47,992,773 | 7,948,110 | |||||||||
| other comprehensive income: | ||||||||||||||||
| unrealized income on marketable securities | -173 | 18 | ||||||||||||||
| change in fair value of preferred stock tranche liability | ||||||||||||||||
| interest income and other income | 19,500 | 53,000 | 5,000 | |||||||||||||
| comprehensive loss attributable to common stockholders | -22,246.75 | -22,754 | -52,969 | |||||||||||||
We provide you with 20 years income statements for Verve Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Verve Therapeutics stock. Explore the full financial landscape of Verve Therapeutics stock with our expertly curated income statements.
The information provided in this report about Verve Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.